Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Ofloxacin · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| Arm 1 | ACTIVE_COMPARATOR | - |
| Arm 2 | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| Ofloxacin | DRUG | Ofloxacin 400 mg po bid plus metronidazole 500 mg po bid for 14 days |
| Avelox (Moxifloxacin, BAY12-8039) | DRUG | Moxifloxacin 400 mg po od for 14 days |
Inclusion Criteria: * Diagnosis of PID based on: pelvic discomfort- Direct lower abdominal tenderness; * Adnexal tenderness on bimanual vaginal examination, * Temperature \> 38.0°C; - Elevated C-reactive protein value (CRP); * Signed PIC/IC Exclusion Criteria: * Pregnancy * Abnormal lab values
Ofloxacin is a small molecule antibiotic used for the treatment of Pelvic Inflammatory Disease (PID), a bacterial infection of the female reproductive organs. It is being developed by Bayer AG for this indication and is currently in Phase 3 clinical development.
Ofloxacin is a fluoroquinolone antibiotic that works by inhibiting bacterial DNA gyrase and topoisomerase IV, enzymes essential for bacterial DNA replication and repair. This mechanism is effective against a broad range of gram-negative and gram-positive bacteria, making it useful in treating pelvic inflammatory disease.
Ofloxacin is developed by Bayer AG, a multinational pharmaceutical company headquartered in Germany. Bayer's stock is traded over-the-counter under the ticker symbol BAYRY. The company is conducting clinical trials to evaluate Ofloxacin for the treatment of Pelvic Inflammatory Disease.
Ofloxacin is in Phase 3 clinical development for the treatment of Pelvic Inflammatory Disease. It is an investigational drug, meaning it has not yet been approved by regulatory authorities. The Phase 3 trial, NCT00683865, has been completed, and the drug is not currently in active clinical trials.
Ofloxacin has been studied in one Phase 3 clinical trial, NCT00683865, titled 'Uncomplicated Pelvic Inflammatory Disease. Treatment With Moxifloxacin.' This randomized, double-blind, active-controlled trial enrolled 749 female participants aged 18 years and older across multiple countries, including Denmark, Finland, France, Germany, and the United Kingdom.
No, Ofloxacin and Moxifloxacin are different antibiotics. Both are fluoroquinolones, but they have distinct chemical structures and spectrums of activity. The clinical trial NCT00683865 compared Ofloxacin to Moxifloxacin for the treatment of Pelvic Inflammatory Disease, but they are not the same drug.